Selva Therapeutics, Inc. is an early stage pharmaceutical company focusing on the development of therapeutics for infectious diseases. Selva’s lead compound, S-001, is highly active against coronaviruses such as SARS-CoV-2 that is responsible for Covid-19. The company is located in San Diego, California.
Selva Lead Program
Coronaviruses must enter host cells to replicate. Cell entry by the virus is mediated by proteases found in the host. S-001 is an inhibitor of these proteases and prevents the virus from binding to receptors needed for entry into the host cell. In addition to activity against coronaviruses, S-001 has shown activity against filoviruses such as Ebola, and the parasite T. cruzi, which is responsible for the development of Chagas disease.